CorriXR Therapeutics is an oncology-focused biotherapeutics development company with a ground-breaking gene editing platform technology
CorriXR is developing a new paradigm for treatment of solid tumors with a unique CRISPR/Cas biomolecular tool that knocks out the gene for the master transcriptional regulator NRF2